Drug intelligence / Profile preview

GDNF variant

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes
Administration: Intracerebral

Overview

GDNF variant is a modified form of glial cell derived neurotrophic factor, a biologic developed by Eli Lilly in collaboration with Medtronic for the treatment of Parkinson's disease. This drug is designed to be delivered directly to targeted brain regions using Medtronic's implantable drug infusion system, aiming to bypass the blood-brain barrier and address the underlying neurodegeneration in Parkinson's disease.

Other names: modified form of glial cell derived neurotrophic factor

Targets

GFRα1 (Glial cell line-derived neurotrophic factor receptor alpha 1)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on GDNF variant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDNF variant.

Explore the full profile